权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cardiovascular Peptides and Myocardial Infarction

心血管肽与心肌梗塞

基本信息

批准号：
7269302
负责人：
John C Burnett
金额：
$ 49.17万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-01 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7269302
关键词：
Acute myocardial infarction Adrenergic Agents Aldosterone Animals Anterior Apoptotic Area Arts Atrial Natriuretic Factor Biological Biological Markers Biology Blood Vessels Blood capillaries Cardiac Cardiac Myocytes Cardiovascular system Cell Survival Cells Collagen Complication Coronary Coronary Arteriosclerosis Development Dilatation - action Disruption Excretory function Fibroblasts Fibrosis Functional disorder Genes Genetic Polymorphism Goals Heart Heart Injuries Heart failure Hormones Hour Human Hypertension Impairment Intravenous Kidney Laboratory Research Lead Magnetic Resonance Imaging Mediating Methodology Modeling Molecular Mus Mutation Myocardial Myocardial Infarction Myocardium Natriuresis Natriuretic Peptides Natural regeneration Nuclear Outcome Oxygen Consumption Pathological Dilatation Peptides Phase Phenotype Phosphotransferases Physiological Plasma Prevention Property Proteins Renal function Renin-Angiotensin-Aldosterone System Reporting Research Research Personnel Risk Sodium Structure System Therapeutic Therapeutic Agents Thinking Time Translational Research Vasodilation Vasodilation disorder Ventricular Ventricular Dysfunction Ventricular Remodeling Wild Type Mouse ZYX gene adrenergic base capillary cardiogenesis clinically relevant day density human study innovation mortality mouse model novel prevent programs promoter repaired response success

项目摘要

DESCRIPTION (provided by applicant): Our objective is to establish that the cardiac peptide BNP is a novel and efficacious therapy for human acute myocardial infarction (AMI) to preserve myocardial structure and function. This highly translational research takes advantage of the cardioprotective and renal enhancing properties of this small and endogenous peptide in protecting the heart from injury and promoting cardiac repair. Our broad unifying hypothesis is that the endogenous natriuretic peptide (NP) system mediates cardiorenal protection and that therapeutic enhancement in experimental and human AMI with exogenous BNP will preserve myocardial structure and function while maintaining renal function. This strategy is based on the biology of BNP that enhances renal function, mediates coronary vasodilatation, reduces myocardial oxygen consumption, suppresses aldosterone release, retards adrenergic activation, induces vascular regeneration, inhibits cardiac fibroblast collagen synthesis and has anti-apoptotic properties. First, we will utilize a murine model of partial proANP gene disruption (Nppa+/-) that has clinical relevance to the recently reported human polymorphism (C664G) that is reported to be characterized by a distruption of the ANP promoter with reduced circulating ANP and risk for ventricular remodeling in human hypertension. This novel genetically altered model has normal cardiac phenotype but demonstrates an exaggerated ventricular hypertrophic and fibrotic response to AMI. In this model with AMI and in wild type (WT) mice we seek to establish cardiorenal protection with 5 days of BNP based therapy. Second, we will extend our research to human AMI investigating the cardiorenal protective properties of 72 hours of BNP therapy initiated at the time of revascularization compared to conventional therapy to preserve myocardial and renal function. Our Specific Aims are as follows: Aim 1: To characterize myocardial structure and function, humoral function and renal function in WT and Nppa+/- mice after AMI; Aim 2: To characterize myocardial structure and function, humoral function and renal function in WT and Nppa+/- mice after AMI in the presence of BNP therapy; and Aim 3: To characterize myocardial structure and function, humoral function and renal function in human AMI in the presence and absence of BNP therapy. For the public, this research may enhance long-term survival after a heart attack. The use of a hormone made in the heart and given at the time of heart attack may help the heart protect and repair itself.

描述（由申请人提供）：我们的目标是建立心脏肽BNP是一种新的有效治疗人类急性心肌梗死（AMI）的方法，以保持心肌结构和功能。这项高度转化的研究利用了这种小内源性肽在保护心脏免受损伤和促进心脏修复方面的心脏保护和肾脏增强特性。我们广泛的统一假设是内源性利钠肽（NP）系统介导心肾保护，外源性BNP在实验性和人类AMI中的治疗增强将在维持肾功能的同时保护心肌结构和功能。这一策略是基于BNP的生物学特性：增强肾功能，介导冠状动脉血管舒张，降低心肌耗氧量，抑制醛固酮释放，延缓肾上腺素能激活，诱导血管再生，抑制心脏成纤维细胞胶原合成，并具有抗凋亡特性。首先，我们将利用部分proANP基因破坏（Nppa+/-）的小鼠模型，该模型与最近报道的人类多态性（C664G）具有临床相关性，该多态性的特征是ANP启动子被破坏，导致循环ANP减少，并增加高血压患者心室重构的风险。这种新的基因改变模型具有正常的心脏表型，但对AMI表现出夸大的心室肥厚和纤维化反应。在AMI模型和野生型（WT）小鼠中，我们试图通过5天的基于BNP的治疗建立心肾保护。其次，我们将把我们的研究扩展到人类AMI，研究在血运重建术时开始的72小时BNP治疗与传统治疗相比，以保护心肌和肾功能的心肾保护特性。我们的具体目的如下：目的1：研究AMI后WT和Nppa+/-小鼠心肌结构和功能、体液功能和肾功能的变化；目的2：在BNP治疗的情况下，观察AMI后WT和Nppa+/-小鼠的心肌结构和功能、体液功能和肾功能；目的3：在存在和不存在BNP治疗的情况下，表征人类AMI的心肌结构和功能、体液功能和肾功能。对于公众来说，这项研究可能会提高心脏病发作后的长期存活率。在心脏病发作时使用一种由心脏产生的激素可以帮助心脏保护和修复自己。